Anacor Will Host a Conference Call Today 8am ET / 5am PT to Discuss Results
PALO ALTO, CA, USA I March 21, 2013 I Anacor Pharmaceuticals (ANAC) today announced positive results from a Phase 2 dose-ranging trial (AN2728-AD-204) of its topical boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728. The study included 86 adolescents (ages 12 – 17) with mild-to-moderate atopic dermatitis, a chronic rash which predominantly affects children and is characterized by inflammation and itching. In this study, lesions treated with AN2728 ointment, 2.0% twice daily for 28 days achieved a 71% improvement from baseline in their Atopic Dermatitis Severity Index (ADSI) score, with 66% of lesions in this treatment group achieving total or partial clearance. AN2728 was generally safe and well-tolerated. Most adverse events were mild and largely unrelated to study drug.
“These results demonstrate a clear dose response across the four dosing regimens and identify the AN2728 ointment, 2.0% BID dosing regimen as optimal for a Phase 3 program, which we expect to initiate around the end of 2013,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals. “In all arms of the study, lesions treated with AN2728 ointment improved throughout the 28 day treatment period. The majority of the improvement occurred within the first week of treatment, which is important to both patients and physicians. AN2728 also continues to demonstrate an excellent safety profile – a key factor in treating this disease that primarily affects children.”
“There is a tremendous clinical need for safe and effective treatments for pediatric atopic dermatitis. It is very exciting to see these promising positive data for a novel molecule with excellent anti-inflammatory properties and that appears very safe to use,” said Lawrence F. Eichenfield, M.D., Chief of Pediatric and Adolescent Dermatology and Professor of Pediatrics and Medicine (Dermatology) at Rady Children’s Hospital, University of California, San Diego. “AN2728 has the potential to be an outstanding addition to the treatment armamentarium for physicians and a great benefit to children with atopic dermatitis.”
The Phase 2 randomized, double-blind, bilateral study enrolled adolescent patients with mild-to-moderate atopic dermatitis. Patients were randomized 1:1 to either once daily (QD) or twice daily (BID) application for 28 days. Patients were instructed to apply AN2728 ointment, 2.0% to one target lesion and AN2728 ointment, 0.5% to a comparable target lesion. The primary endpoint was the change from baseline ADSI score, which is the sum of the severity scores of five clinical features (erythema, pruritus, exudation, excoriation and lichenification) from 0 (none) to 3 (severe) for each feature, for a total score of 0 to 15. Additional endpoints included differences in ADSI component subscores and safety.
A clear dose response was demonstrated in this study, with AN2728 ointment, 2.0% BID yielding the greatest improvement. At Day 29, the following results were observed:
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dosing Regimen |
|
|
|
|
|
|
|
|
% Improvement from Baseline ADSI |
|
|
|
|
% of Lesions Achieving Total or Partial
Clearance
|
| AN2728 2.0%, BID |
|
|
|
|
|
|
|
|
71% |
|
|
|
|
62% |
| AN2728 0.5%, BID |
|
|
|
|
|
|
|
|
62% |
|
|
|
|
50% |
| AN2728 2.0%, QD |
|
|
|
|
|
|
|
|
63% |
|
|
|
|
41% |
| AN2728 0.5%, QD |
|
|
|
|
|
|
|
|
54% |
|
|
|
|
43% |
| |
|
|
|
|
|
|
|
|
|
| Dosing Regimen |
|
|
|
|
|
|
|
|
% Improvement in Component Score from Baseline |
| |
|
|
|
|
|
|
|
|
Erythema |
|
|
|
|
|
|
|
|
Excoriation |
|
|
|
|
|
|
|
|
Exudation |
|
|
|
|
|
|
|
|
Lichenification |
|
|
|
|
|
|
|
|
Pruritus |
| AN2728 2.0%, BID |
|
|
|
|
|
|
|
|
67% |
|
|
|
|
|
|
|
|
78% |
|
|
|
|
|
|
|
|
80% |
|
|
|
|
|
|
|
|
54% |
|
|
|
|
|
|
|
|
79% |
| AN2728 0.5%, BID |
|
|
|
|
|
|
|
|
59% |
|
|
|
|
|
|
|
|
64% |
|
|
|
|
|
|
|
|
56% |
|
|
|
|
|
|
|
|
49% |
|
|
|
|
|
|
|
|
75% |
| AN2728 2.0%, QD |
|
|
|
|
|
|
|
|
55% |
|
|
|
|
|
|
|
|
73% |
|
|
|
|
|
|
|
|
76% |
|
|
|
|
|
|
|
|
46% |
|
|
|
|
|
|
|
|
73% |
| AN2728 0.5%, QD |
|
|
|
|
|
|
|
|
52% |
|
|
|
|
|
|
|
|
57% |
|
|
|
|
|
|
|
|
52% |
|
|
|
|
|
|
|
|
44% |
|
|
|
|
|
|
|
|
63% |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
About Atopic Dermatitis and Current Treatment Options
Atopic dermatitis is a chronic rash characterized by inflammation and itching. In 2007, Datamonitor reported that atopic dermatitis affected approximately 40 million people across the seven major pharmaceutical markets. The condition most commonly appears in childhood, with up to 20% of children in the United States affected, and it can persist into adulthood. Skin affected by atopic dermatitis can often be broken from scratching which can allow bacterial or viral access and lead to secondary infections. Current atopic dermatitis treatments attempt to reduce inflammation and itching to maintain the protective integrity of the skin. Antibiotics, antihistamines, topical corticosteroids and topical immunomodulators, either as monotherapy or in combination, are the current standard of care for atopic dermatitis. However, these can be limited in utility due to insufficient efficacy, side effects or safety concerns. The most recently approved novel topical treatments for atopic dermatitis were topical immunomodulators, Protopic (tacrolimus) and Elidel (pimecrolimus), approved in 2000 and 2001, respectively. Protopic and Elidel achieved combined sales of over $500 million in 2004, prior to receiving Black Box warnings from the FDA in early 2005.
Conference Call and Webcast
Anacor will host a conference call today at 8:00 a.m. ET / 5:00 a.m. PT to discuss the results of this Phase 2 trial in atopic dermatitis. The call can be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and can be accessed on the Events and Presentations page, under Investors, on the company’s website at www.anacor.com and will be available for three months following the call.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered eight compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds — tavaborole, an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis. In addition to its two lead programs, Anacor has discovered three other wholly-owned clinical product candidates — AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK ‘052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC, or GSK. GSK has returned all rights to the compound to us and we are considering our options for further development, if any, of this compound. We have also discovered three other compounds that we have out-licensed for further development — two are licensed to Eli Lilly and Company for the treatment of animal health indications and the third compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative, or DNDi, for human African trypanosomiasis (HAT, or sleeping sickness).
SOURCE: Anacor Pharmaceuticals
Post Views: 358
Anacor Will Host a Conference Call Today 8am ET / 5am PT to Discuss Results
PALO ALTO, CA, USA I March 21, 2013 I Anacor Pharmaceuticals (ANAC) today announced positive results from a Phase 2 dose-ranging trial (AN2728-AD-204) of its topical boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728. The study included 86 adolescents (ages 12 – 17) with mild-to-moderate atopic dermatitis, a chronic rash which predominantly affects children and is characterized by inflammation and itching. In this study, lesions treated with AN2728 ointment, 2.0% twice daily for 28 days achieved a 71% improvement from baseline in their Atopic Dermatitis Severity Index (ADSI) score, with 66% of lesions in this treatment group achieving total or partial clearance. AN2728 was generally safe and well-tolerated. Most adverse events were mild and largely unrelated to study drug.
“These results demonstrate a clear dose response across the four dosing regimens and identify the AN2728 ointment, 2.0% BID dosing regimen as optimal for a Phase 3 program, which we expect to initiate around the end of 2013,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals. “In all arms of the study, lesions treated with AN2728 ointment improved throughout the 28 day treatment period. The majority of the improvement occurred within the first week of treatment, which is important to both patients and physicians. AN2728 also continues to demonstrate an excellent safety profile – a key factor in treating this disease that primarily affects children.”
“There is a tremendous clinical need for safe and effective treatments for pediatric atopic dermatitis. It is very exciting to see these promising positive data for a novel molecule with excellent anti-inflammatory properties and that appears very safe to use,” said Lawrence F. Eichenfield, M.D., Chief of Pediatric and Adolescent Dermatology and Professor of Pediatrics and Medicine (Dermatology) at Rady Children’s Hospital, University of California, San Diego. “AN2728 has the potential to be an outstanding addition to the treatment armamentarium for physicians and a great benefit to children with atopic dermatitis.”
The Phase 2 randomized, double-blind, bilateral study enrolled adolescent patients with mild-to-moderate atopic dermatitis. Patients were randomized 1:1 to either once daily (QD) or twice daily (BID) application for 28 days. Patients were instructed to apply AN2728 ointment, 2.0% to one target lesion and AN2728 ointment, 0.5% to a comparable target lesion. The primary endpoint was the change from baseline ADSI score, which is the sum of the severity scores of five clinical features (erythema, pruritus, exudation, excoriation and lichenification) from 0 (none) to 3 (severe) for each feature, for a total score of 0 to 15. Additional endpoints included differences in ADSI component subscores and safety.
A clear dose response was demonstrated in this study, with AN2728 ointment, 2.0% BID yielding the greatest improvement. At Day 29, the following results were observed:
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dosing Regimen |
|
|
|
|
|
|
|
|
% Improvement from Baseline ADSI |
|
|
|
|
% of Lesions Achieving Total or Partial
Clearance
|
| AN2728 2.0%, BID |
|
|
|
|
|
|
|
|
71% |
|
|
|
|
62% |
| AN2728 0.5%, BID |
|
|
|
|
|
|
|
|
62% |
|
|
|
|
50% |
| AN2728 2.0%, QD |
|
|
|
|
|
|
|
|
63% |
|
|
|
|
41% |
| AN2728 0.5%, QD |
|
|
|
|
|
|
|
|
54% |
|
|
|
|
43% |
| |
|
|
|
|
|
|
|
|
|
| Dosing Regimen |
|
|
|
|
|
|
|
|
% Improvement in Component Score from Baseline |
| |
|
|
|
|
|
|
|
|
Erythema |
|
|
|
|
|
|
|
|
Excoriation |
|
|
|
|
|
|
|
|
Exudation |
|
|
|
|
|
|
|
|
Lichenification |
|
|
|
|
|
|
|
|
Pruritus |
| AN2728 2.0%, BID |
|
|
|
|
|
|
|
|
67% |
|
|
|
|
|
|
|
|
78% |
|
|
|
|
|
|
|
|
80% |
|
|
|
|
|
|
|
|
54% |
|
|
|
|
|
|
|
|
79% |
| AN2728 0.5%, BID |
|
|
|
|
|
|
|
|
59% |
|
|
|
|
|
|
|
|
64% |
|
|
|
|
|
|
|
|
56% |
|
|
|
|
|
|
|
|
49% |
|
|
|
|
|
|
|
|
75% |
| AN2728 2.0%, QD |
|
|
|
|
|
|
|
|
55% |
|
|
|
|
|
|
|
|
73% |
|
|
|
|
|
|
|
|
76% |
|
|
|
|
|
|
|
|
46% |
|
|
|
|
|
|
|
|
73% |
| AN2728 0.5%, QD |
|
|
|
|
|
|
|
|
52% |
|
|
|
|
|
|
|
|
57% |
|
|
|
|
|
|
|
|
52% |
|
|
|
|
|
|
|
|
44% |
|
|
|
|
|
|
|
|
63% |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
About Atopic Dermatitis and Current Treatment Options
Atopic dermatitis is a chronic rash characterized by inflammation and itching. In 2007, Datamonitor reported that atopic dermatitis affected approximately 40 million people across the seven major pharmaceutical markets. The condition most commonly appears in childhood, with up to 20% of children in the United States affected, and it can persist into adulthood. Skin affected by atopic dermatitis can often be broken from scratching which can allow bacterial or viral access and lead to secondary infections. Current atopic dermatitis treatments attempt to reduce inflammation and itching to maintain the protective integrity of the skin. Antibiotics, antihistamines, topical corticosteroids and topical immunomodulators, either as monotherapy or in combination, are the current standard of care for atopic dermatitis. However, these can be limited in utility due to insufficient efficacy, side effects or safety concerns. The most recently approved novel topical treatments for atopic dermatitis were topical immunomodulators, Protopic (tacrolimus) and Elidel (pimecrolimus), approved in 2000 and 2001, respectively. Protopic and Elidel achieved combined sales of over $500 million in 2004, prior to receiving Black Box warnings from the FDA in early 2005.
Conference Call and Webcast
Anacor will host a conference call today at 8:00 a.m. ET / 5:00 a.m. PT to discuss the results of this Phase 2 trial in atopic dermatitis. The call can be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and can be accessed on the Events and Presentations page, under Investors, on the company’s website at www.anacor.com and will be available for three months following the call.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered eight compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds — tavaborole, an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis. In addition to its two lead programs, Anacor has discovered three other wholly-owned clinical product candidates — AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK ‘052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC, or GSK. GSK has returned all rights to the compound to us and we are considering our options for further development, if any, of this compound. We have also discovered three other compounds that we have out-licensed for further development — two are licensed to Eli Lilly and Company for the treatment of animal health indications and the third compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative, or DNDi, for human African trypanosomiasis (HAT, or sleeping sickness).
SOURCE: Anacor Pharmaceuticals
Post Views: 358
